Boston Scientific's EVP sells $5.8 million in stock

Boston Scientific's EVP Joseph Fitzgerald sold 56,372 shares at $102.88 on June 4, 2025, totaling $5.8 million, under a pre-established Rule 10b5-1 trading plan, while also exercising options for the same amount at $26.15 per share. Concurrently, Boston Scientific reaffirmed its Q2 and full-year 2025 guidance despite discontinuing its Acurate TAVR systems due to regulatory hurdles, a move analysts view strategically, potentially benefiting competitors like Edwards Lifesciences; analysts maintain positive ratings on Boston Scientific, citing strong performance from products like Farapulse and Watchman.

Analysis

Joseph Michael Fitzgerald, EVP and Group President of Cardiology at Boston Scientific Corp. (BSX), executed a significant stock transaction on June 4, 2025, selling 56,372 shares for approximately $5.8 million at a weighted average price of $102.88, near the stock's 52-week high of $107.17. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025, suggesting it was not driven by immediate adverse information. Concurrently, Fitzgerald exercised options to acquire an identical number of shares at $26.15 each, a common practice often related to covering exercise costs and taxes, and he retains a substantial direct holding of 178,342 shares post-transaction. Operationally, Boston Scientific has reaffirmed its second quarter and full-year 2025 guidance for sales and adjusted EPS, demonstrating confidence despite discontinuing its Acurate neo2 and Acurate Prime TAVR systems. This TAVR discontinuation, which followed discussions with regulators highlighting additional clinical and regulatory hurdles for U.S. approval, impacts products that generated over $200 million in EMEA sales in 2024 with double-digit growth, though no U.S. revenue was anticipated. Analyst sentiment remains broadly positive: Piper Sandler and TD Cowen maintained positive outlooks with price targets of $115.00, citing strong performance from key products like Farapulse and Watchman. Citi reiterated a Buy rating with a $125.00 target, viewing the TAVR discontinuation as a strategic move that could benefit competitors such as Edwards Lifesciences (EW), while Needham analysts (PT $115.00) anticipate positive impact from upcoming CHAMPION trial results for the Watchman device. The company, with a $152 billion market capitalization and a 'GREAT' financial health score, has delivered a strong 35% return over the past year, reflecting its strategic focus on growth opportunities in the medical device sector.

Key Decisions for Investors

• Investors should interpret the EVP's stock sale in the context of the pre-established Rule 10b5-1 plan and simultaneous option exercise, noting his significant remaining equity stake which indicates continued alignment with company performance.
• Boston Scientific's reaffirmed 2025 guidance, despite the Acurate TAVR system discontinuation, signals resilience; attention should be directed towards the growth trajectory of core products like Farapulse and Watchman, and the upcoming CHAMPION trial results for the Watchman device.
• The strategic decision to exit the Acurate TAVR systems, viewed positively by analysts, may free up resources for higher-growth areas, though investors should monitor potential market share shifts to competitors like Edwards Lifesciences.
• Considering BSX stock is trading near its 52-week high after a 35% annual gain, and given the general market context of high valuations, investors should carefully weigh the strong analyst price targets ($115-$125) and positive fundamentals against current valuation levels before initiating or adding to positions.